Foghorn Therapeutics (FHTX)
NASDAQ:FHTX
Total Valuation
Foghorn Therapeutics has a market cap or net worth of $259.46M. The enterprise value is $240.98M.
Market Cap$259.46M
Enterprise Value$240.98M
Share Statistics
Foghorn Therapeutics has 58,700,245 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding58,700,245
Owned by Insiders1.10%
Owned by Institutions42.81%
Financial Efficiency
Foghorn Therapeutics’s return on equity (ROE) is 0.68 and return on invested capital (ROIC) is -58.95%.
Return on Equity (ROE)0.68
Return on Assets (ROA)-0.37
Return on Invested Capital (ROIC)-58.95%
Return on Capital Employed (ROCE)-0.59
Revenue Per Employee275.97K
Profits Per Employee-663.24K
Employee Count112
Asset Turnover0.16
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Foghorn Therapeutics is ―. Foghorn Therapeutics’s PEG ratio is 0.18.
PE Ratio―
PS Ratio11.00
PB Ratio-3.13
Price to Fair Value-3.13
Price to FCF-3.95
Price to Operating Cash Flow-3.50
PEG Ratio0.18
Income Statement
In the last 12 months, Foghorn Therapeutics had revenue of 30.91M and earned -74.28M in profits. Earnings per share was -1.18.
Revenue30.91M
Gross Profit27.58M
Operating Income-82.11M
Pretax Income-74.28M
Net Income-74.28M
EBITDA-78.78M
Earnings Per Share (EPS)-1.18
Cash Flow
In the last 12 months, operating cash flow was -86.10M and capital expenditures -50.00K, giving a free cash flow of -86.15M billion.
Operating Cash Flow-86.10M
Free Cash Flow-86.15M
Free Cash Flow per Share-1.47
Dividends & Yields
Foghorn Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.75
52-Week Price Change29.24%
50-Day Moving Average5.47
200-Day Moving Average5.08
Relative Strength Index (RSI)32.25
Average Volume (3m)157.41K
Important Dates
Foghorn Therapeutics upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateMar 11, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Foghorn Therapeutics as a current ratio of 2.73, with Debt / Equity ratio of -38.04%
Current Ratio2.73
Quick Ratio2.73
Debt to Market Cap<0.01
Net Debt to EBITDA0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Foghorn Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Foghorn Therapeutics EV to EBITDA ratio is -3.81, with an EV/FCF ratio of -3.49.
EV to Sales9.72
EV to EBITDA-3.81
EV to Free Cash Flow-3.49
EV to Operating Cash Flow-3.49
Balance Sheet
Foghorn Therapeutics has $158.89M in cash and marketable securities with $41.27M in debt, giving a net cash position of $117.62M billion.
Cash & Marketable Securities$158.89M
Total Debt$41.27M
Net Cash$117.62M
Net Cash Per Share$2.00
Tangible Book Value Per Share-$1.72
Margins
Gross margin is 29.78%, with operating margin of -265.64%, and net profit margin of -240.33%.
Gross Margin29.78%
Operating Margin-265.64%
Pretax Margin-240.33%
Net Profit Margin-240.33%
EBITDA Margin-254.86%
EBIT Margin-265.64%
Analyst Forecast
The average price target for Foghorn Therapeutics is $11.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.67
Price Target Upside164.03% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-3.91%
EPS Growth Forecast37.89%